deltatrials
Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01782287

Proteome-based Immunotherapy of Lung Cancer Brain Metastases

Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer

Sponsor: Blokhin's Russian Cancer Research Center

Conditions Neoplasm Metastasis
Interventions Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
Updated 6 times since 2017 Last updated: Oct 11, 2017 Started: Dec 31, 2012 Primary completion: Dec 31, 2018 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01782287, this PHASE2/PHASE3 trial focuses on Neoplasm Metastasis and remains ongoing. Sponsored by Blokhin's Russian Cancer Research Center, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotEnrolling By Invitation~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotEnrolling By Invitation~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2/PHASE3

    Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2_PHASE3

    Status: Enrolling By Invitation → Unknown Status

  5. Jun 2018 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE2_PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Enrolling By Invitation PHASE2_PHASE3

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Blokhin's Russian Cancer Research Center
  • National Institute of Regenerative Medicine
  • NeuroVita Clinic
  • Russian Foundation of Technological Development
  • SRC Bioclinicum
  • The Serbsky State Scientific Center for Social and Forensic Psychiatry
Data source: NeuroVita Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations